Login to Your Account

Refusal to File Stalls EpiCept's AML Drug; Another Trial?

By Jennifer Boggs

Tuesday, August 24, 2010
Shares of EpiCept Corp. plunged 38.3 percent Monday after the FDA refused to accept its new drug application for Ceplene (histamine dihydrochloride) in combination with interleukin-2 as a maintenance therapy for acute myeloid leukemia and, instead, recommended an additional pivotal trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription